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Evaluation of pre-analytical factors 
affecting plasma DNA analysis
Havell Markus1, Tania Contente-Cuomo1, Maria Farooq1, Winnie S. Liang1,2, Mitesh J. Borad3, 
Shivan Sivakumar4, Simon Gollins5, Nhan L. Tran1,6, Harshil D. Dhruv1, Michael E. Berens  1, 
Alan Bryce  3, Aleksandar Sekulic1,3, Antoni Ribas7, Jeffrey M. Trent1,2, Patricia M. LoRusso8 & 
Muhammed Murtaza  1,3
Pre-analytical factors can significantly affect circulating cell-free DNA (cfDNA) analysis. However, there 
are few robust methods to rapidly assess sample quality and the impact of pre-analytical processing. 
To address this gap and to evaluate effects of DNA extraction methods and blood collection tubes on 
cfDNA yield and fragment size, we developed a multiplexed droplet digital PCR (ddPCR) assay with 
5 short and 4 long amplicons targeting single copy genomic loci. Using this assay, we compared 7 
cfDNA extraction kits and found cfDNA yield and fragment size vary significantly. We also compared 
3 blood collection protocols using plasma samples from 23 healthy volunteers (EDTA tubes processed 
within 1 hour and Cell-free DNA Blood Collection Tubes processed within 24 and 72 hours) and found no 
significant differences in cfDNA yield, fragment size and background noise between these protocols. 
In 219 clinical samples, cfDNA fragments were shorter in plasma samples processed immediately after 
venipuncture compared to archived samples, suggesting contribution of background DNA by lysed 
peripheral blood cells. In summary, we have described a multiplexed ddPCR assay to assess quality of 
cfDNA samples prior to downstream molecular analyses and we have evaluated potential sources of 
pre-analytical variation in cfDNA studies.
Analysis of circulating cell-free DNA from plasma (cfDNA) has several potential diagnostic applications in pre-
natal, transplant and cancer medicine1–4. In patients with cancer, a fraction of cfDNA carries tumor-specific 
somatic mutations. Circulating tumor DNA (ctDNA) analysis relies on detection and quantification of these 
mutations, against a background of cfDNA contributed by peripheral blood cells and other tissues. Total cfDNA 
and tumor-specific ctDNA levels in plasma vary considerably across cancer patients, cancer types and disease 
stages as well as during longitudinal follow-up of each patient5,6. Several recent reports have described sensitive 
molecular methods for analysis of ctDNA7–9. However, comparison between published ctDNA studies is often 
challenging because of differences in collection and processing of plasma samples. Our understanding of how 
pre-analytical factors affect performance and results of ctDNA assays is limited10.
cfDNA fragments in plasma have a modal fragment size of 160–180 bp, corresponding to DNA protected in 
mono-nucleosomes11. One challenge when analyzing plasma DNA is the variable contribution of high molecular 
weight (HMW) DNA resulting from lysis of peripheral blood cells during blood processing12–15. HMW DNA 
is not intended to be part of the molecular readout during ctDNA analysis but it can affect PCR and sequenc-
ing results. High fractions of HMW DNA in plasma can complicate PCR and tagmentation-based sequencing 
because these methods will incorporate intact DNA in a sample, potentially biasing the data towards wild-type 
alleles and increasing false negative results for somatic mutations. In contrast, ligation-based library preparation 
from cfDNA does not require any additional DNA fragmentation and therefore excludes intact DNA. However, 
if the contribution of intact DNA is not taken into account during sample quantification, library preparation 
can vary in performance. Ideally, rapid processing of blood samples as soon as possible after venipuncture can 
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overcome these issues but real-time processing of samples is challenging in clinical environments. With grow-
ing interest in cfDNA-based diagnostics, several solutions have emerged to streamline pre-analytical processing. 
These include special blood collection tubes that contain cell-stabilizing preservative to minimize lysis of periph-
eral blood cells for up to several days after venipuncture. In addition, cfDNA-focused extraction kits have been 
introduced that claim preferential extraction of fragmented cfDNA over HMW DNA from the same sample.
There is scarcity of robust methods that allow quality assessment of low input cfDNA samples and there 
are few published comparisons between pre-analytical solutions. Here, we present a multiplexed digital PCR 
approach that can reliably assess cfDNA quantity and contribution of HMW DNA. We use this assay to compare 
cfDNA extraction kits and to perform quality assessment of plasma samples across multiple archival and pro-
spective clinical cohorts of cancer patients. We also evaluate the performance and downstream effects of blood 
collection tubes in matched plasma samples from healthy volunteers.
Results
Droplet Digital PCR to assess cfDNA concentration and fragment size. To enable reliable assess-
ment of amplifiable DNA concentration and fragment size using minimal quantities of cfDNA, we designed 
a multiplexed ddPCR assay targeting 9 single copy genomic loci16. We included 5 short PCR amplicons with 
mean product size of 71 bp (range 67–75 bp) and corresponding probes labeled with FAM as well as 4 long PCR 
amplicons with mean product size of 471 bp (range 439–522 bp) and corresponding probes labeled with TET 
(Fig. 1 and Supplemental Table 1). We confirmed each individual assay amplified linearly over a range of input 
concentrations using quantitative PCR (qPCR; Supplemental Fig. 1). When multiplexed together on ddPCR, we 
expected two populations of droplets with distinct fluorescence, each representing the sum of products from the 
two amplicon sets. Assuming no copy number changes, the number of FAM-positive droplets represents 5 times 
the number of haploid genome equivalents (GEs) with fragments long enough to be amplified using short ampli-
cons. Similarly, the number of TET-positive droplets represents 4 times the GEs with fragment sizes amplifiable 
using long amplicons. We calculated low molecular weight cfDNA concentration as the difference between short 
and long GEs. Within FAM- and TET-positive droplets, we observed distinct droplet clusters that corresponded 
with differences in amplicon sizes. For example, when analyzing intact DNA using this assay, we found an ampli-
con of 522 bp clustered at lower fluorescence levels compared to two other amplicons of 439 and 444 bp, consistent 
with earlier inhibition of amplification in individual droplets containing longer PCR amplicons. We used this 
feature to compare quantitative performance of amplicons with each other and found high correlation when 
analyzing intact DNA samples (Supplemental Fig. 2).
To evaluate the performance of the multiplexed assay, we analyzed control DNA with different predetermined 
fragment sizes (holding the DNA concentration constant across comparisons). We compared observed results 
with expected PCR performance, simulated using the exponential distribution, given amplicon and fragment 
sizes. Observed ddPCR results agreed with expected results for 150, 300, 500 and 1,000 bp fragments remarkably. 
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Figure 1. Schematic representation of a multiplexed droplet digital PCR approach for measuring cfDNA 
quantity and evaluating fragment size. We expect two populations of droplets with distinct fluorescence, each 
representing the sum of products from the two amplicon sets. The number of FAM-positive droplets represents 
5 times the number of haploid genome equivalents (GEs) with fragments long enough to be amplified using 
short amplicons. Similarly, the number of TET-positive droplets represents 4 times the GEs with fragment 
sizes amplifiable using long amplicons. We calculate low molecular weight (LMW) cfDNA concentration as the 
difference between average short and long GEs. Primer sequences and amplicon sizes are listed in Supplemental 
Table 1 and amplicon positions relative to common SNPs are shown in Supplemental Figure 6.
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For example, using a 71 bp amplicon and input of 150 bp DNA fragments, we expect to recover ~62% and we 
observed 75% recovery using short amplicons in our assay (Fig. 2a). We also compared ddPCR results with 
DNA quantification by fluorometry (Qubit) and found strong correlation (Pearson r = 0.908, p = 1.18 × 10−6, 
Supplemental Fig. 3). We further compared ddPCR results with DNA quantification using an electrophoretic 
approach (Agilent BioAnalyzer DNA High Sensitivity Assay) and found strong correlation between LMW con-
centrations measured using the two methods (Pearson R: 0.809, p = 0.0026, Supplemental Figure 4). To assess 
whether ddPCR quantification of input DNA can help overcome variability in sequencing results, we measured 
the concentration of low molecular weight (LMW) DNA in 5 control plasma samples to prepare and sequence 
12 exome libraries made from 1, 2 and 5 ng LMW DNA. Besides input quantity, all other library preparation 
conditions including number of PCR cycles were similar between these replicates. Library size and diversity was 
estimated from 0.83–1.66 million read pairs per sample. As expected, library diversity correlated strongly with 
input DNA quantities (Pearson r = 0.938, p = 2.48 × 10−7; Fig. 2b and Supplemental Table 2).
Comparison of cfDNA extraction kits. To compare performance of cfDNA extraction kits and min-
imize the contribution of biological variation, we obtained a pooled control plasma sample. We compared 7 
different extraction kits marketed for cfDNA extraction including 3 spin column-based methods and 4 magnetic 
beads-based methods (labeled A-G, see Supplemental Table 3). For each kit, we performed 10 replicates of DNA 
extraction from 1 mL plasma and quantified cfDNA yield and fragment size using ddPCR. We found wide var-
iability in yield and fragment size across these kits (ANOVA p = 5.01 × 10−11 and p = 1.16 × 10−11 respectively, 
Fig. 3 and Supplemental Table 4). Highest median yield of LMW cfDNA was obtained using Kit A that uses spin 
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Figure 2. Evaluation of ddPCR assay performance. (a) Comparison of ddPCR measurements with expected 
results when using control DNA of known fragment size as template. Solid lines with crosses show measured 
ddPCR results. DNA concentration was held constant for this experiment, isolating the effect of fragment 
size on final measurements. Dotted lines with circles show simulated data, generated using the exponential 
distribution with period set to fragment size. *Simulated data was generated assuming 10,000 bp fragments, 
a much larger period compared to the PCR amplicon sizes used here. Corresponding ddPCR measurement 
was performed on intact genomic DNA (without sonication). (b) Evaluation of sequencing library diversity 
obtained with cfDNA input amounts measured using the ddPCR assay. The first y-axis on the left shows 
projected diversity of the library in millions of unique fragments. On the second y-axis (right), library diversity 
has been converted into number of genome equivalents, by calculating the quotient between the projected 
diversity and fragments expected per haploid genome. Assuming 44 Mb exome captured region and 170 bp 
fragment size, we expect ~0.26 million fragments per haploid genome. 5, 4, and 3 individual libraries were 
prepared for 1, 2, and 5 ng cfDNA input respectively. These data are also listed in Supplemental Table 2.
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columns for cfDNA extraction (1,936 GEs/mL of plasma, n = 10). Median LMW fraction for Kit A was 89%. The 
median yield of LMW DNA using Kit B was not significantly different than Kit A but the results were more vari-
able (1,760 LMW copies/mL plasma, t-test p = 0.427). Amongst methods based on magnetic beads, Kit E showed 
the highest yield of LMW DNA (median 1,515 LMW copies/mL, n = 10) and a LMW fraction comparable to Kit 
A (median 90%). In comparison to Kit A, the yield was significantly lower (t-test p = 9.46 × 10−5).
Comparison of blood collection protocols. To investigate how cfDNA yield and LMW fractions were 
affected by blood collection tubes and protocols, we collected 3 blood samples each from 23 healthy volunteers 
(12 males and 11 females): one EthyleneDiamineTetraacetic Acid (EDTA) tube processed within 1 hour and two 
Cell-free DNA Blood Collection Tubes (BCT) stored at ambient temperature for 24 hours and 72 hours prior 
to processing (labeled here as BCT 24 hr and BCT 72 hr respectively). We processed all samples identically and 
extracted cfDNA using QIAamp Circulating Nucleic Acid kit (QIAGEN). We measured cfDNA yield and frag-
ment size using ddPCR. Mean LMW GEs/mL plasma for EDTA, BCT 24 hr, and BCT 72 hr were 1,925, 1,591, 
and 1,514 respectively with no significant difference between collection protocols (ANOVA p = 0.439, Fig. 4a and 
Supplemental Table 5). LMW fractions for EDTA, BCT 24 hr, and BCT 72 hr were 87%, 88%, and 90% respec-
tively with no significant difference (ANOVA p = 0.083, Fig. 4b).
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Figure 3. Evaluation of cfDNA extraction methods using ddPCR. Kits labeled A-C use spin columns and kits 
labeled D-G use magnetic beads for cfDNA isolation. For each extraction kit, n = 10 individual extractions were 
performed successfully, starting with 1 mL plasma volume except for kit B (n = 9) and kit G (n = 7). Aliquots 
from a single pool of 250 mL commercially obtained control plasma sample were used for these experiments. 
(a) Comparison of cfDNA yield (in LMW fragments/mL of plasma) across 7 extraction kits. An outlier at 5,306 
LMW fragments/mL for Kit B is not shown to enhance scaling. Concentration of LMW fragments in DNA 
samples was calculated as the difference between average short and long GEs (as shown in Fig. 1). To calculate 
concentration in input plasma samples, the LMW fragment concentration in DNA samples was multiplied by 
elution volume and divided by input volume of plasma used during DNA extraction (1 mL). (b) Comparison 
of LMW fraction across 7 extraction kits. LMW fraction was calculated as LMW fragment concentration 
(difference between average short and long GEs) as a fraction of average short GEs. These data are also listed in 
Supplemental Table 4.
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Figure 4. (a,b,c) Evaluation of blood collection protocols for cfDNA analysis using ddPCR and digital targeted 
sequencing. (a,b) Comparison of cfDNA yield (in LMW fragments/mL of plasma) and LMW fraction across 
3 blood collection methods. Outliers at 0.67 LMW fraction for EDTA and at 0.71 LMW fraction for BCT 24 hr 
are not shown in (b) to enhance scaling. Paired samples from healthy volunteers were collected for this analysis. 
Comparison between EDTA, BCT 24 hr samples and BCT 72 hr samples showed no significant difference for 
yield or LMW fraction (ANOVA p-values > 0.05). Concentration of LMW fragments in DNA samples was 
calculated as the difference between average short and long GEs (as shown in Fig. 1). To calculate concentration 
in input plasma samples, the LMW fragment concentration in DNA samples was multiplied by the elution 
volume used at the time of plasma DNA extraction and divided by the volume of plasma used. LMW fraction 
was calculated as LMW fragment concentration (difference between average short and long GEs) as a fraction 
of average short GEs. (c) Comparison of depth-adjusted GMR observed across collection protocols. Pairwise 
comparisons between EDTA and BCT 24 hr samples (n = 12 pairs) and between EDTA and BCT 72 hr samples 
(n = 13) showed no significant difference between collection protocols (paired t-test p > 0.05). (d) Comparison 
of LMW fraction between archived retrospective samples and samples processed using gold standard protocols 
for ctDNA analysis, showing significant difference between the two groups (n = 219 plasma samples, t-test 
p = 2.302 × 10−7). Symbols indicate cohort numbers with details in Supplemental Tables 6 and 7. Samples in the 
gold standard cohorts were collected in EDTA tubes, spun for 10 mins at 820 g, aliquoted to 1 mL, spun again 
for 10 mins at maximum speed (16,000–20,000 g) and stored at −80 °C, within 1-3 hours. Details of sample 
processing for all cohorts are described in Supplemental Table 6. For 4 archived samples, LMW fraction was 
measured as a negative number. Potential drivers of a negative LMW fraction include (1) sampling variation 
when input DNA is nearly 100% intact but concentration is low; (2) copy number variations affecting one or 
more loci in a very high tumor fraction plasma sample and 3) underestimated short GEs due to overloading, 
when input DNA is nearly 100% intact and concentration is very high. Our assay targets 5 short amplicons 
and 4 long amplicons. Assuming intact DNA, when a ddPCR reaction is overloaded, the assumption of single 
droplet occupancy will be violated earlier for short amplicons and despite Poisson correction for droplet 
loading, we are likely to underestimate short GEs. For 2 of 4 samples with negative LMW fraction (−18.9 and 
−22.5%), we measured the highest long GEs of all included samples, suggesting the input DNA was nearly 
100% intact and we underestimated short GEs in these measurements due to overloading. In the third and 
fourth sample (LMW fraction −3.4 and −1.5%), we measured a few additional copies of the genome using long 
amplicons compared to short (314 long vs. 309 short GEs and 490 long vs. 474 short GEs), suggesting sampling 
noise and nearly 100% intact DNA.
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To assess whether cell-stabilizing preservative would affect background noise in cfDNA sequencing, we pre-
pared targeted sequencing libraries using a molecular tagging approach that can help distinguish non-reference 
alleles arising in the original template molecules from errors introduced during PCR amplification. We sequenced 
43 samples including all 3 pairs from 12 individuals and 7 additional samples. We generated an average of 7.64 
million read pairs per sample and achieved mean unique coverage in the target region of 37.0 read families 
(with an average 3.92 members/read family). To measure background noise, we calculated global nucleotide 
mismatch rate (GMR) as the sum of the number of read families with non-reference alleles divided by the sum of 
unique coverage across all targeted loci (additional details in Methods). GMR per million bases was 37.8 ± 12.2, 
30.8 ± 9.11 and 30.8 ± 7.77 for EDTA, BCT 24 hr and BCT 72 hr samples respectively (mean ± standard devia-
tion). GMR between paired samples from the same individuals was highly correlated across tube types (Pearson 
r = 0.652, 0.647 and 0.758, p = 0.022, 0.017 and 0.003 for the three pairwise comparisons, Supplemental Figure 5). 
This suggests that biological noise (in vivo) was a much larger contributor to measured GMR instead of noise 
introduced during sample processing or analysis. Since depth of coverage would determine our ability to measure 
low-abundance noise, we adjusted GMR by unique depth of coverage and found no significant difference between 
EDTA and BCT 24 hr as well as EDTA and BCT 72 hr samples (paired t-test p = 0.998, n = 12 pairs and p = 0.451, 
n = 13 pairs respectively, Fig. 4c).
Evaluation of cfDNA fragment size in clinical samples. To evaluate the extent to which background 
DNA from peripheral cell lysis affects cfDNA analysis in archived retrospective samples, we evaluated a cohort 
of 219 clinical samples collected across 7 cohorts and multiple collection sites (Supplemental Table 6). Using the 
ddPCR assay, we found that LMW fractions were significantly lower in archived samples (cohorts 1 and 2, n = 70 
samples, median LMW fraction: 82.5%) compared to plasma samples collected prospectively for cfDNA analysis 
and immediately processed using current gold standard protocols (cohorts 3–7, n = 149 samples, median LMW 
fraction: 91.1%, t-test p = 2.302 × 10–7, Fig. 4d and Supplemental Tables 5 and 7).
Discussion
Variation in pre-analytical processing of plasma samples can affect results of cfDNA analysis12. Circulating 
cell-free DNA is predominantly fragmented and delays between venipuncture and isolation of plasma can 
lead to higher background of intact DNA contributed by lysis of peripheral blood cells13. This affects PCR and 
tagmentation-based sequencing methods by diluting the measured mutation fractions and it affects ligation-based 
sequencing methods by lowering effective template available for analysis. We have developed a multiplexed 
droplet digital PCR approach to reliably assess amplifiable quantities of cfDNA and estimate the contribution 
of high molecular weight background DNA in a single step. As an upfront sample quality assessment assay, this 
approach can help optimize input quantities to achieve reproducible performance in sequencing experiments. 
The assay design targets 9 different regions in the genome, lowering minimum input DNA quantity needed for 
quality assessment. qPCR or digital PCR assays that target 1-2 loci can be biased by locus-specific amplification 
bias or by somatic copy number changes in plasma samples from advanced cancer patients17. Instead, we rely 
on average readouts across multiple targets to achieve high precision from limited quantities of cfDNA and to 
accommodate the wide range of total cfDNA concentrations found in patients with cancer (particularly when 
implemented in ddPCR with millions of partitions). Although widespread aneuploidy in the tumor can still affect 
our approach, targeting multiple loci limits the impact of any single copy number alteration on the final quanti-
fication. Nevertheless, a PCR based approach to quantify cfDNA may under- or over-estimate total cfDNA levels 
in plasma samples from a fraction of patients with advanced, widely aneuploid cancers and very high fractions of 
tumor-derived DNA in plasma.
Several new solutions to streamline cfDNA extraction have been introduced recently including magnetic-bead 
based approaches but published reports have not compared these with existing methods17–20. To provide an 
update and compare cfDNA extraction performance using a robust approach, we evaluated seven commercially 
available kits marketed for cfDNA extraction and found that QIAamp Circulating Nucleic Acid kit provided 
the highest cfDNA yield and low molecular weight fractions. Newer methods that use magnetic beads for DNA 
extraction may be more automatable and in our results, the MagMAX Cell-free DNA Isolation kit provided the 
highest yield and low molecular weight fractions amongst such workflows.
To overcome the need for rapid processing of plasma samples, special blood collection tubes are available 
that include a preservative to prevent lysis of peripheral blood cells for up to several days at room temperature21. 
Current applications for cfDNA analysis in prenatal diagnostics rely on relative representation of genomic regions 
but in patients with cancer, there is need for detection of mutations at very low fractional abundance and preserv-
ative induced noise could lead to false positives. In paired samples from healthy volunteers, we found no evidence 
that cfDNA yield or fragment size was significantly different between EDTA tubes processed within 1 hour of 
collection and BCT tubes stored at ambient temperature and processed 72 hours after collection. These results are 
in agreement with published observations22–25. In addition, we also extensively explored whether preservative in 
BCT tubes induced any pre-analytical noise using digital targeted sequencing. To ensure that we could measure 
pre-analytical noise separately from any errors introduced during library preparation, we used a molecularly 
tagged sequencing strategy. We found no evidence that global mutation rate (adjusted for depth of sequencing) is 
any different in blood stored in BCT tubes at ambient temperature for up to 72 hours after collection as compared 
to samples collected in EDTA tubes and processed within 1 hour. Interestingly, we observed that GMR was highly 
correlated between independent replicates from the same individual across blood processing protocols, even after 
thorough filtering for common and private germline SNPs. This suggests that once sequencing errors are filtered 
out, biological noise introduced in vivo is the predominant contributor to GMR instead of pre-analytical errors 
introduced in vitro. Such biological noise may arise from non-specific somatic mutations (potentially originating 
in circulating blood cells) or extracellular damage to cfDNA during circulation. Although we cannot distinguish 
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between these mechanisms based on our results, this observation warrants further study particularly as the field 
investigates circulating tumor DNA analysis for early detection of cancer.
There are multiple limitations of this study that must be acknowledged. Library preparation kits differ in their 
efficiency and performance and can be affected by multiple factors such as adapter composition, input DNA 
concentration and ligation time. While the absolute measurements of library yield and diversity may not be valid 
for other library preparation methods, accurate quantification and size assessment of input cfDNA will still be 
relevant. Similarly, several factors can affect DNA extraction yield including input plasma volumes and elution 
volumes. When comparing cfDNA extraction methods, we minimized biological background by testing 70 repli-
cates of 1 mL each from a single pooled plasma sample. Extraction performance of the tested kits may differ from 
our results if a different volume of plasma is used. Moreover, our analysis is limited to 7 commercially available 
cfDNA extraction solutions including 3 kits that use spin columns and 4 kits that use magnetic beads. There are 
several additional solutions for cfDNA extraction available and our results will not be directly relevant for any 
solutions not tested in this study. For comparison of blood collection and processing protocols, we performed 
paired analysis of samples and found no appreciable differences in background noise between EDTA and BCT 
tubes. Our effective sample size for the sequencing-based comparison is limited to 13 pairs and that could limit 
power to detect subtle differences in pre-analytical error rates but there are no indications of even a trend towards 
a difference in depth-adjusted GMR between collection protocols. In addition, comparison of blood process-
ing protocols was performed on samples obtained from healthy volunteers and we cannot directly comment on 
whether tumor-specific mutant DNA will behave similarly.
In summary, we have developed a droplet digital PCR based approach to assess quantity and quality of plasma 
DNA samples to improve performance of downstream sequencing assays. We presented comparison of several 
methods for cfDNA extraction and blood collection for cfDNA and their potential effects on downstream anal-
ysis. We now routinely use this assay for quality assessment of all plasma samples processed and analyzed for 
ctDNA studies in our lab. We find significant differences in quality between archived samples and prospectively 
collected plasma samples, processed rapidly for ctDNA analysis, highlighting the importance and need for appro-
priate pre-analytical processing of samples. Since archived samples from clinical trials are often accompanied by 
long-term follow-up and clinical annotation, their use can be critical to evaluate clinical utility of ctDNA analysis 
in cancer patients. The ddPCR approach we describe here will be useful to assess quality of archived samples 
prior to analysis and to inform interpretation of downstream results. Our findings can benefit the design of future 
studies and clinical trials by helping minimize the contribution of pre-analytical variability in circulating tumor 
DNA analysis.
Methods
Droplet Digital PCR to assess quantity and fragment size. We designed a multiplexed ddPCR assay 
targeting 9 single copy genomic loci16. We included 5 short PCR amplicons with mean product size of 71 bp 
(range 67–75 bp) and corresponding probes labeled with FAM as well as 4 long PCR amplicons with mean prod-
uct size of 471 bp (range 439–522 bp) and corresponding probes labeled with TET (Fig. 1 and Supplemental 
Table 1). We used PrimerQuest (Integrated DNA Technologies) to design these assays, evaluated them to avoid 
known polymorphic loci (snapshots from UCSC genome browser indicate common SNPs relative to primer and 
probe loci in Supplemental Figure 6). We used in silico PCR to confirm each amplicon yielded a single product 
and no cross products when used in multiplex, using a command-line version of UCSC In Silico PCR to evaluate 
primers in batch.
We prepared digital PCR reactions at 50 μL volume using 25 μL of 2 × KAPA PROBE FAST Master Mix (Kapa 
Biosystems), 2 μL of 5 mM dNTP Mix (Kapa), 2 μL of 25 × Droplet Stabilizer (RainDance Technologies), 9 μL 
of 100 μM primer mix (pooled equimolarly), 1.68 μL of 20 μM each probe (IDT), 0.25 μL molecular biology 
grade water and 2-10 μL of input DNA. We generated droplets using RainDrop Digital PCR Source Instrument 
(RainDance), performed thermocycling using DNA Engine Tetrad 2 (Bio-Rad Laboratories) with the following 
parameters: 1 cycle of 3 min at 95 °C, 50 cycles of 15 sec at 95 °C and 1 min at 60 °C with a 0.5 °C/sec ramp from 
95 °C to 60 °C, 1 cycle of 98 °C for 10 min and hold at 4 °C forever. We measured droplet fluorescence using 
RainDrop Digital PCR Sense Instrument (RainDance) and analyzed results using accompanying software.
Identification of positive droplets requires setting fluorescence thresholds (gates) for each ddPCR assay 
(Fig. 1). We compared results across intact genomic DNA and no template controls to identify thresholds for this 
assay. We calculated fractional loss of volume (dead volume) as the difference between measured number of intact 
droplets of expected size (5 pL) and number of expected droplets (10 million droplets for 50 μL reactions). Any 
reactions with > 50% loss of volume were excluded from further analysis.
Using uniform gates across all samples, we measured two populations of droplets: FAM-labeled droplets with 
short amplicons and TET-labeled droplets with long amplicons. We calculated short and long haploid Genome 
Equivalents (GEs) by dividing short and long droplet counts by number of targeted assays (5 and 4 respectively). 
We further calculated GE concentration by accounting for input DNA volume. We calculated LMW fragment 
concentration by taking the difference between long and short GEs (Fig. 1). We calculated LMW fragment con-
centration in plasma as the product between LMW fragment concentration in the DNA sample and elution 
volume divided by plasma volume used for DNA extraction. We calculated LMW fraction as the LMW fragment 
concentration in DNA sample expressed a fraction of short GEs.
Evaluation of assay performance. For any given PCR reaction, yield is affected by amplicon size and tem-
plate fragment size. To evaluate whether our ddPCR assay performed as expected, we analyzed known quantities 
of sheared DNA fragments with predetermined size and compared the results with expected theoretical yields. To 
generate experimental data, we analyzed 4 aliquots of 0.6 ng/μL human genomic DNA (Sigma Aldrich), sheared 
by sonication to achieve fragment sizes of 150 bp, 300 bp, 500 bp and 1,000 bp. To estimate theoretical yield, we 
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performed simulations of DNA fragmentation as described previously26. Assuming a DNA molecule spanning 
2,500 bp on either side of the average amplicon size for each set (5,071 bp for short amplicons and 5,471 bp for 
long amplicons), we generated break points by sampling from an exponential distribution with a rate representing 
the corresponding fragment size (150, 300, 500 or 1,000 bp). We determined that a molecule will be “missed” by 
an amplicon if a DNA break fell within the amplicon region (bound by 5′ ends of the two primers). We sampled 
50,000 molecules to determine overall frequency of missed molecules for each combination of amplicon size and 
fragment size.
Comparison of cfDNA extraction kits. We obtained 250 mL of a control pooled plasma sample collected 
with K2 EDTA additive from BioreclamationIVT. Upon receipt, the sample was thawed and stored in 1 mL ali-
quots at −80 °C until further analysis. We compared 7 different extraction kits marketed for cfDNA extraction 
including 3 spin column-based methods and 4 magnetic beads-based methods (labeled A-G, see Supplemental 
Table 3). Manufacturer recommended protocols for plasma DNA extraction were followed. Prior to each extrac-
tion, plasma aliquots were centrifuged at 14,000 g for 10 minutes to remove any cellular debris.
Comparison of blood collection protocols. To compare cfDNA yield, fragment size and sequencing 
noise across blood collection protocols, we collected plasma samples from healthy volunteers. We collected 
8–10 mL blood in K2 EDTA BD Vacutainer tubes and two Cell-Free DNA BCT (Streck) from each volunteer21. 
EDTA tube was processed within 1 hour of collection. cfDNA BCT were stored at ambient temperature and 
processed 24 and 72 hours after collection. Samples were centrifuged at 820 g for 10 min at room temperature. 
1 mL aliquots of plasma were further centrifuged at 16,000 g for 10 mins to pellet any remaining cellular debris. 
The supernatant was stored at −80 °C until DNA extraction. DNA was extracted using the QIAamp Circulating 
Nucleic Acid kit (QIAGEN). cfDNA yield and fragment size were evaluated using ddPCR. Baseline sequencing 
noise was evaluated using digital sequencing, targeting a panel of recurrent cancer genes.
Clinical samples. Healthy volunteer and clinical plasma samples included in comparison of immediately 
processed and archived samples were collected after obtaining informed consent under multiple independent 
clinical protocols, all approved by Western IRB (protocol number 20142638). All experiments were performed in 
accordance with relevant guidelines and regulations. Samples from 7 independent clinical cohorts were included 
in this analysis, including patients diagnosed with melanoma, cholangiocarcinoma and rectal cancer as well as 
healthy volunteers. Sample processing conditions and number of samples from each cohort are described in 
Supplemental Table 6. 7 samples, all from the same ddPCR chip, were excluded from this analysis due to > 50% 
loss of volume during ddPCR. Median dead volume across remaining samples was 10.4% (n = 219 samples).
Sequencing library preparation. For assessment of sequencing performance guided by ddPCR results, 
we quantified cfDNA from control plasma samples (commercially obtained) using ddPCR and prepared whole 
genome sequencing libraries using ThruPLEX DNA-Seq (Rubicon Genomics), as per manufacturer’s instructions. 
We compared performance across 1, 2 and 5 ng amounts of input DNA and concentrated samples to achieve 
10 μL starting volume if needed (using vacuum concentration). We assigned sample specific barcodes to each 
library, quantified them using qPCR and pooled them at equimolar concentrations for target enrichment. We 
performed exome enrichment using NimbleGen SeqCap EZ Human Exome v3 kit (Roche), as per manufacturer’s 
instructions except the use of xGen Universal Blocking Oligos – TS HT-i5 and TS HT-i7 (IDT). We quantified 
all enriched exome libraries using qPCR and pooled at equimolar concentrations for sequencing. We performed 
sequencing on MiSeq (Illumina) to generate 75 bp paired-end reads and a 6 bp barcode read.
For comparison of background noise between blood collection tubes, we prepared whole genome sequenc-
ing libraries from 1 ng cfDNA from volunteer plasma samples using ThruPLEX Tag-seq (Rubicon). This kit 
introduces a 6 bp random molecular tag on both sides of DNA fragments, making it possible to distinguish any 
non-reference alleles (true mutations or pre-analytical noise) in the original template molecule from PCR noise 
introduced during library preparation. We quantified the libraries and pooled them for target capture using 
xGen® Pan-Cancer Panel (IDT), following manufacturer’s instructions.
Sequencing data analysis. We demultiplexed sequencing data based on sample-specific barcodes and con-
verted to fastq files using Picard tools v2.2.1, allowing 1 bp mismatch and requiring minimum base quality of 30. 
We aligned sequencing reads to the human genome hg19 using bwa mem v0.6.227. We sorted and indexed bam 
files using samtools v1.3.128 and calculated library diversity using Picard tools.
For data comparing background noise across blood collection tubes, we added a barcode (BC) tag comprised 
of the two paired 6 bp unique molecular identifiers (UMIs) to each aligned read. We parsed these BAM files using 
a custom R script to identify UMI families and assign read groups as follows: For each set of reads that started 
and ended at the same genomic positions, we sorted UMI pairs by the number of exact duplicates observed. We 
used the most frequent UMI pair in this set to seed the first read family. For the remaining reads, if either of the 
2 UMIs in a pair were within a Hamming distance of 1 from the corresponding seed UMI, we assigned them to 
the same read family. For any UMIs not assigned in the first cycle, we repeated this process starting with the next 
most frequent UMI pair until all reads had been assigned read families. We grouped reads from the same family 
by adding RG tags to the BAM files. To facilitate computational processing, we assumed fragment sizes in our 
libraries would not exceed 1,000 bp.
Once all reads were assigned RG tags, we generated pileups per read-family using samtools mpileup. Each 
read family with ≥ 3 members was included in further analysis. We required ≥ 80% of reads supporting a 
non-reference allele to call a variant. All variants overlapping with dbSNP v147 were removed. To avoid any pri-
vate SNPs, we filtered out positions covered by < 10 read families or total non-reference allele fraction ≥ 20%. We 
calculated global nucleotide mismatch rate (GMR) as the sum of the number of read families with non-reference 
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alleles divided by the sum of unique coverage across all targeted loci. To account for variability in depth of cover-
age between samples, we adjusted GMR for average unique coverage in each sample.
Data Availability Statement. The datasets generated during and analyzed during the current study are 
available from the corresponding author on reasonable request.
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